186 related articles for article (PubMed ID: 15125753)
21. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
22. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
23. Hypersensitivity syndrome associated with efavirenz therapy.
Bossi P; Colin D; Bricaire F; Caumes E
Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772
[No Abstract] [Full Text] [Related]
24. Can efavirenz be taken in the morning?
Skeie L; Maeland A
Scand J Infect Dis; 2006; 38(11-12):1089-91. PubMed ID: 17148083
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
26. Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.
van Ramshorst MS; Kekana M; Struthers HE; McIntyre JA; Peters RP
BMC Pediatr; 2013 Aug; 13():120. PubMed ID: 23941256
[TBL] [Abstract][Full Text] [Related]
27. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Yazaki H; Kikuchi Y; Oka S
Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
[No Abstract] [Full Text] [Related]
28. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
29. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
30. Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis.
Kratz JD; El-Shazly AY; Mambuque SG; Demetria E; Veldkamp P; Anderson TS
Malawi Med J; 2016 Dec; 28(4):185-187. PubMed ID: 28321284
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz: practicalities, considerations and new issues.
Moyle G
Int J Clin Pract Suppl; 1999 Jun; 103():30-4. PubMed ID: 10622041
[TBL] [Abstract][Full Text] [Related]
32. Neuropsychiatric effects of efavirenz: delayed onset.
Dawson S; Woods C
Int J STD AIDS; 2005 Nov; 16(11):769-70. PubMed ID: 16303077
[No Abstract] [Full Text] [Related]
33. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
34. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
[TBL] [Abstract][Full Text] [Related]
35. A new HAART on the horizon says the proof is in the potency.
AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
[TBL] [Abstract][Full Text] [Related]
36. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
Pérez-Molina JA; Domingo P; Martínez E; Moreno S
J Antimicrob Chemother; 2008 Aug; 62(2):234-45. PubMed ID: 18480167
[TBL] [Abstract][Full Text] [Related]
37. Gynecomastia and HAART.
Post JJ
AIDS Read; 2000 May; 10(5):314. PubMed ID: 10851722
[No Abstract] [Full Text] [Related]
38. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
[TBL] [Abstract][Full Text] [Related]
39. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
[No Abstract] [Full Text] [Related]
40. Cortisol serum levels and their relationship to certain antiretroviral drugs.
Collazos J; Ibarra S; Loureiro M
Scand J Infect Dis; 2004; 36(6-7):480-2. PubMed ID: 15307572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
